Menu
GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
    • Status of Assessments
    • Timeline of Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Contact Us
    • Call for Nomination
    • Topic Nomination
  • AUXILIARY MENU
  • GOVPH
  • Home
  • HTA Governance
    • Universal Health Care Act
    • Administrative Order on HTA
    • Philippine HTA Process Guide
    • Philippine HTA Methods Guide
    • Philippine HTA Code of Conduct
  • About Us
    • Mission/Vision
    • Health Technology Assessment Council (HTAC)
    • Health Technology Assessment Division (HTAD)
    • HTA Philippines Annual Report
      • 2021 HTA Annual Report
      • 2020 HTA Annual Report
      • 2019 HTA Annual Report
    • Road to HTA Institutionalization
    • External Partners
  • Assessments
    • Status of Assessments
    • Timeline of Assessments
  • Issuances
  • Evidence Briefs
  • FAQs
  • Get Involved with Us
    • Contact Us
    • Call for Nomination
    • Topic Nomination

Issuances

[DEPARTMENT PERSONNEL ORDER NO. 2022- 1245] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Drugs

May 10, 2022

preliminary recommendation for the inclusion of Potassium Citrate 1620 mg (15 mEq) tablet in the PNF.

April 13, 2022

[DEPARTMENT PERSONNEL ORDER NO. 2022- 1102] Authority for Select Department of Health (DOH) Personnel to conduct a Hybrid Workshop on the Development of Guidelines in the Creation of the Philippine Essential Medical Device List (PEMDL) on April 22, 2022 in Metro Manila,

April 7, 2022

[DEPARTMENT CIRCULAR NO. 2022- 0183] Opening of the 2022 Call for topic nomination

April 1, 2022

[DEPARTMENT CIRCULAR NO. 2022- 0164] Health Technology Assessment Council (HTAC) Recommendation for reinclusion of vasopressin 20 iU/ml (IM/IV) in the Philippine National Formulary

March 23, 2022

preliminary recommendation for the inclusion of rituximab 1400 mg/ 11.7 mL solution for subcutaneous (SC) injection for the treatment of non-Hodgkin’s lymphoma

March 4, 2022

preliminary recommendation for the inclusion of vasopressin 20 IU/mL (IM/IV)

February 11, 2022

[DEPARTMENT CIRCULAR NO. 2022- 0074] Nomination to the Health Technology Assessment Council (HTAC) Subcommittee on Drugs

February 9, 2022

[DEPARTMENT CIRCULAR NO. 2022- 0015] Health Technology Assessment Council (HTAC) Recommendation to include Sambong 250mg Tablet in the Philippine national Formulary

January 21, 2022

preliminary recommendation for the non-inclusion of pertuzumab for human epidermal growth factor receptor 2 (HER2)-positive breast cancer

January 20, 2022

Posts navigation

  • Newer Newer
    • 1
    • 2
    • 3
    • …
    • 7
  • Older Older
685921
Users Today : 422
This Month : 4845
Total Users : 685921
Your IP Address : 35.172.223.251
Philippine Standard Time: